Gilead Sciences Inc (GILD)
66.74
+0.58
(+0.88%)
USD |
NASDAQ |
Apr 19, 16:00
66.77
+0.03
(+0.04%)
After-Hours: 19:08
Gilead Sciences Enterprise Value: 100.06B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 100.06B |
| April 17, 2024 | 101.02B |
| April 16, 2024 | 101.49B |
| April 15, 2024 | 102.04B |
| April 12, 2024 | 102.44B |
| April 11, 2024 | 103.16B |
| April 10, 2024 | 102.50B |
| April 09, 2024 | 104.77B |
| April 08, 2024 | 104.12B |
| April 05, 2024 | 104.32B |
| April 04, 2024 | 104.28B |
| April 03, 2024 | 105.95B |
| April 02, 2024 | 107.45B |
| April 01, 2024 | 108.43B |
| March 28, 2024 | 108.89B |
| March 27, 2024 | 108.59B |
| March 26, 2024 | 107.85B |
| March 25, 2024 | 108.06B |
| March 22, 2024 | 108.09B |
| March 21, 2024 | 108.69B |
| March 20, 2024 | 109.80B |
| March 19, 2024 | 109.09B |
| March 18, 2024 | 108.90B |
| March 15, 2024 | 109.44B |
| March 14, 2024 | 110.09B |
| Date | Value |
|---|---|
| March 13, 2024 | 112.24B |
| March 12, 2024 | 111.17B |
| March 11, 2024 | 111.47B |
| March 08, 2024 | 111.22B |
| March 07, 2024 | 109.40B |
| March 06, 2024 | 108.12B |
| March 05, 2024 | 108.57B |
| March 04, 2024 | 107.65B |
| March 01, 2024 | 107.72B |
| February 29, 2024 | 107.46B |
| February 28, 2024 | 108.21B |
| February 27, 2024 | 108.61B |
| February 26, 2024 | 108.52B |
| February 23, 2024 | 109.27B |
| February 22, 2024 | 108.31B |
| February 21, 2024 | 108.83B |
| February 20, 2024 | 107.38B |
| February 16, 2024 | 106.81B |
| February 15, 2024 | 109.06B |
| February 14, 2024 | 108.65B |
| February 13, 2024 | 109.26B |
| February 12, 2024 | 110.41B |
| February 09, 2024 | 109.43B |
| February 08, 2024 | 109.60B |
| February 07, 2024 | 110.37B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
76.35B
Minimum
Dec 30 2020
131.76B
Maximum
Dec 08 2022
102.37B
Average
103.87B
Median
Enterprise Value Benchmarks
| Amgen Inc | 194.48B |
| Johnson & Johnson | 357.61B |
| Eli Lilly and Co | 731.61B |
| CymaBay Therapeutics Inc (DELISTED) | 3.443B |
| Arcus Biosciences Inc | 589.43M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.429B |
| Revenue (Quarterly) | 7.114B |
| Total Expenses (Quarterly) | 5.106B |
| EPS Diluted (Quarterly) | 1.14 |
| Gross Profit Margin (Quarterly) | 70.62% |
| Profit Margin (Quarterly) | 20.09% |
| Earnings Yield | 6.74% |
| Operating Earnings Yield | 10.49% |
| Normalized Earnings Yield | 7.867 |